TCA
GILD icon

Transcend Capital Advisors’s Gilead Sciences GILD Stock Holding History

Transcend Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$801K Sell
6,343
-290
-4% -$38.2K 0.05% 318
2026
Q1 		$924K Buy
6,633
+128
+2% +$17.9K 0.07% 247
2025
Q4 		$798K Buy
6,505
+301
+5% +$36.6K 0.06% 272
2025
Q3 		$689K Buy
6,204
+416
+7% +$47.3K 0.05% 318
2025
Q2 		$642K Buy
5,788
+318
+6% +$33.8K 0.05% 297
2025
Q1 		$613K Sell
5,470
-149
-3% -$15.4K 0.04% 324
2024
Q4 		$519K Sell
5,619
-2,787
-33% -$251K 0.04% 342
2024
Q3 		$705K Buy
8,406
+89
+1% +$6.79K 0.05% 321
2024
Q2 		$571K Buy
8,317
+45
+0.5% +$3K 0.04% 326
2024
Q1 		$606K Buy
8,272
+1,614
+24% +$124K 0.05% 293
2023
Q4 		$539K Buy
6,658
+72
+1% +$5.6K 0.05% 297
2023
Q3 		$494K Buy
6,586
+490
+8% +$37.7K 0.05% 291
2023
Q2 		$470K Buy
6,096
+95
+2% +$7.58K 0.04% 310
2023
Q1 		$498K Sell
6,001
-18,980
-76% -$1.57M 0.05% 290
2022
Q4 		$2.14M Sell
24,981
-1,540
-6% -$122K 0.23% 108
2022
Q3 		$1.64M Buy
26,521
+510
+2% +$32.2K 0.18% 134
2022
Q2 		$1.61M Buy
26,011
+88
+0.3% +$5.45K 0.17% 144
2022
Q1 		$1.54M Buy
25,923
+8,296
+47% +$530K 0.14% 167
2021
Q4 		$1.28M Hold
17,627
– – 0.11% 191
2021
Q3 		$1.19M Sell
17,627
-128
-0.7% -$8.99K 0.11% 196
2021
Q2 		$1.22M Sell
17,755
-230
-1% -$15.4K 0.18% 134
2021
Q1 		$1.16M Sell
17,985
-2,261
-11% -$146K 0.14% 162
2020
Q4 		$1.18M Sell
20,246
-19
-0.1% -$1.15K 0.16% 148
2020
Q3 		$1.28M Buy
20,265
+4,627
+30% +$321K 0.23% 97
2020
Q2 		$1.2M Sell
15,638
-3,954
-20% -$303K 0.39% 74
2020
Q1 		$1.47M Buy
+19,592
New +$1.35M 0.44% 68

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Transcend Capital Advisors's GILD Position: Q2 2026 in Review

Transcend Capital Advisors reduced its Gilead Sciences (GILD) stake by 4.4% in Q2 2026, selling an estimated $38.2K and leaving 6,343 shares worth $801K. The position accounts for 0.05% of the portfolio, ranked #318.

Transcend Capital Advisors first reported a position in GILD in Q1 2020 and has held it in 26 quarters since. The position peaked at $2.14M in Q4 2022. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Transcend Capital Advisors held 6,343 shares of Gilead Sciences worth $801K as of Q2 2026.
  • Transcend Capital Advisors sold 290 Gilead Sciences shares in Q2 2026, an estimated $38.2K.
  • Gilead Sciences made up 0.05% of Transcend Capital Advisors's portfolio in Q2 2026, its #318 holding.
  • Transcend Capital Advisors first reported a position in Gilead Sciences in Q1 2020 and has held it in 26 quarters since.
  • Transcend Capital Advisors's Gilead Sciences position peaked at $2.14M in Q4 2022.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.